ADHD is being recognised more often, in more people, and earlier than it was a decade ago. Adult referrals have climbed, women and girls who were missed for years are finally being assessed, and the public conversation has shifted from "does this even exist" to "how do I get help". That shift matters, because recognition is the first step towards treatment that works. The picture is not perfect, waiting lists are long and medicine supply has been patchy, but the direction of travel is genuinely encouraging.
Recognition is improving across the board
The clearest change is who is now being seen. ADHD was long treated as a childhood condition that boys grew out of, which left a generation of adults, and most women, undiagnosed. That assumption has not survived the evidence. Clinical recognition of adult ADHD and of inattentive presentations has improved steadily, and services have had to respond to demand that was always there but rarely counted. More people understanding that lifelong difficulty with focus, organisation and follow-through can have a name is, on its own, a meaningful development.
What the treatment picture actually looks like
ADHD treatment in the UK is set out in NICE NG87, and the core of it has been stable for years because it works. Treatment is multimodal: medication where it is indicated, alongside psychoeducation, skills-based work and changes to environment and routine. Medication does most of the heavy lifting on attention and impulse control where a prescriber judges it appropriate. The rest of the package helps people build systems around a brain that regulates attention differently. Neither alone is usually enough, and that has not changed.
Are there new ADHD medications coming
This is where headlines tend to outrun reality. The licensed medicines used in the UK, the stimulants and the non-stimulants such as atomoxetine and guanfacine, are well established and well studied. Research into new compounds and new formulations is ongoing, but a promising study is not the same as a licensed treatment you can be prescribed next month. The honest answer is that the existing options are effective for most people, and the more immediate gains are likely to come from better access and better titration rather than a single new drug. Be wary of any source promising a breakthrough cure; ADHD is managed, not cured.
The most useful developments are rarely the dramatic ones. Better recognition and steadier access change more lives than any single headline.
Medication supply and what it means for you
Anyone on ADHD medication in recent years will know that supply has been unreliable, with intermittent shortages of certain stimulant products. The MHRA and the Department of Health have issued guidance to prescribers during these periods, and the NHS ADHD information is a sensible place to check the current position. If your usual medicine is unavailable, a prescriber can discuss alternatives. This is frustrating rather than dangerous, and it does not undo the progress in how ADHD is understood and treated. It is worth knowing the common side effects to watch for so you can have an informed conversation if a switch is needed.
How research is shaping the conversation
The research base on ADHD is large and consistent. It is one of the most heritable conditions in psychiatry, it is not caused by parenting or diet, and the evidence for treatment is strong. What is developing is the detail: a better understanding of how ADHD presents differently across the lifespan, how it co-occurs with anxiety, depression and autism, and how emotional regulation sits at the centre of the picture rather than at the edge. None of this rewrites the basics. It sharpens them, and it helps clinicians tailor support rather than treating everyone the same.
Where therapy and skills work fit in
Medication is not the whole answer, and it does not teach skills. Approaches such as cognitive behavioural therapy for ADHD help with the patterns medication does not reach: procrastination, the gap between intention and action, the emotional fallout of years of near misses. The evidence for structured psychological work as an adjunct to medication is real, and access to it is slowly improving as services recognise that a prescription on its own leaves a lot undone.
Access is the development that matters most
For most people, the bottleneck has never been the science; it has been getting seen. NHS waiting lists for adult ADHD assessment have been long, in many areas very long, and that gap is where the genuine frustration sits. The hopeful development here is that the routes into assessment have widened. Right to Choose in England allows people to ask for assessment through a different provider where their local service is overwhelmed, and private CQC-registered providers offer another path. Neither is a small decision, and both should be approached with eyes open, but the existence of real alternatives is a meaningful change from a decade ago, when waiting was often the only option.
What to be cautious about
A more open conversation about ADHD has a downside worth naming. Where there is demand, there is marketing, and the space now carries plenty of unregulated coaching, supplements and online "assessments" promising fast answers. The progress that counts is in proper clinical recognition and access to evidence-based care, not in products that trade on the same optimism for profit. Treat any claim of a quick fix, a cure or a guaranteed result as a reason for scepticism rather than hope. Real developments are checkable against sources like NICE and the NHS; marketing rarely survives that test.
What this means in practice
- ADHD is being recognised in more adults and more women than ever, which is a real and welcome change.
- The treatment framework under NICE NG87 is stable because it works; be sceptical of anyone promising a cure or a single miracle drug.
- Medication supply has been patchy at times. If your usual product is unavailable, a prescriber can discuss alternatives rather than leaving you stuck.
- The strongest gains for most people come from better access and careful titration, supported by skills-based work, not from waiting for a breakthrough.
If you have suspected ADHD for a while, the developments that matter are the ones that get you assessed and supported. A first step can be as simple as booking an appointment to talk it through, or starting on ADHD medication review where a diagnosis is already in place. The conversation around ADHD has moved forward; the practical question is whether you are getting the support that progress was meant to deliver.
